Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAA | Q9Y263 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391736 | 0.77 | ALDH1A1 (0.62) | PLAAALPGALDH1A1CYP19A1TBXAS1 | |
| SCHEMBL28357612 | 0.74 | ALDH1A1 (0.39) | ALDH1A1CYP1A2 | |
| SCHEMBL11196216 | 0.72 | PLAA (0.44) | PLAAALPGALDH1A1ESR1CYP19A1 | |
| SCHEMBL9911549 | 0.71 | ALDH1A1 (0.47) | ALPGALDH1A1 | |
| SCHEMBL3232702 | 0.71 | MEN1 (0.50) | ALDH1A1CYP1A2 | |
| SCHEMBL2824968 | 0.70 | — | — | |
| SCHEMBL30989344 | 0.70 | TDP1 (0.41) | PLAAALPGALDH1A1ESR1CYP19A1 | |
| SCHEMBL15682636 | 0.67 | FOLH1 (0.41) | CYP19A1 | |
| SCHEMBL20665996 | 0.66 | GRIN2B (0.37) | ALDH1A1GRIN2B | |
| SCHEMBL19268182 | 0.65 | PTGS2 (0.39) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | PLAA 4879/4885ALPG 4431/4885ALDH1A1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.